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Abstract
 
Activation of the transcription factor signal transducer and activator of transcription (STAT)5 is
involved in various aspects of hematopoiesis, affecting cell proliferation, differentiation, and cell
survival. Constitutive activation of STAT5 has also been associated with leukemic transformation.
We overexpressed the constitutively active mutant STAT5A(1
 
*
 
6) in human cord blood
CD34
 
  
 
cells and evaluated the effects on the hematopoietic potential of stem cells in a variety
of in vitro and in vivo systems. The observed phenotypic changes were correlated with differential
gene expression patterns induced by STAT5A(1
 
*
 
6). Our data indicate that a persistent activation
of STAT5A in human hematopoietic stem and progenitor cells results in their enhanced self-
renewal and diverts differentiation to the erythroid lineage.
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*
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Introduction
 
Hematopoiesis is initiated by a relatively small number of
multipotent self-renewing hematopoietic stem cells (HSCs)
that generate large numbers of differentiated progeny by a
process of amplification and progressive lineage restriction.
The process of hematopoietic differentiation involves the
generation of multilineage progenitors that are restricted to
either the myeloid or lymphoid lineages (the common my-
eloid progenitor [1] and the common lymphoid progenitor
[2]), and further differentiation of these pluripotent cells
generates mature erythroid, megakaryocytic, myeloid, or
lymphoid cells (3).
HSC self-renewal and hematopoietic differentiation are
tightly controlled by multiple positive and negative regulatory
elements, but mechanisms modulating the balance between
self-renewal and entrance into a differentiation program
are poorly understood. By loss of function (gene targeting)
or gain of function (ectopic expression) experiments, a
number of transcription factors have been suggested to be
involved in HSC self-renewal, including HOXB4 (4),
NOTCH1 (5), and BMI1 (6, 7). Ectopic expression of
HOXB4 in murine bone marrow resulted in a rapid expan-
sion of the HSC pool, which retained full lymphomyeloid
regenerative potential (4). Similar results have been described
in human CD34
 
  
 
cells isolated from cord blood (CB), al-
though high expression levels of HOXB4 resulted in a
profound in vivo competitive growth advantage of HSCs,
but an impairment of lymphomyeloid differentiation (8).
Overexpression of NOTCH1 in mouse bone marrow re-
sulted in enhanced stem cell self-renewal and a decreased
differentiation with a preferential lymphoid over myeloid
commitment when differentiation did occur (5). More
recently, 
 
bmi1
 
 
 
/
 
  
 
knockout mice, which have a normal
number of HSCs in the fetal liver, were generated, but
postnatal 
 
bmi1
 
 
 
/
 
  
 
mice have reduced numbers of HSCs in
the marrow, which contribute only transiently to hemato-
poiesis upon transplantation (6, 7). The WNT3A/
 
 
 
-catenin
(9) and sonic hedgehog (10) pathways have also been
shown to promote murine HSC self-renewal and oligo-
clonal lymphomyeloid differentiation potential in vivo.
Upon lineage commitment, HSCs generate progeny that
initiate increased expression of lineage-specific genes with
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the coordinate silencing of genes that are not required. For
example, the common myeloid progenitor will express my-
eloid-specific genes (e.g., myeloperoxidase, G-CSFR,
cathepsin G, and C/EBP
 
 
 
), the megakaryocytic/erythroid
progenitor will express genes such as 
 
 
 
-globin, GATA1,
and EPOR, and the common lymphoid progenitor will
express lymphoid-specific genes (e.g., PAX5 and 
 
 
 
5; refer-
ences 1 and 2). However, molecular mechanisms underly-
ing these decision checkpoints are still poorly understood.
It is believed that a subtle balance exists between the ex-
pression of genes involved in differentiation, genes that are
cell cycle related, and pro-/antiapoptotic genes, to ensure
appropriate expansion, survival, and differentiation.
A variety of cytokines and growth factors have been
identified that perform crucial roles in checkpoint decisions
during hematopoiesis. Many of these involve the activation
of STAT transcription factors. Seven mammalian STAT
family members have been identified thus far, STAT1–6,
with two different genes encoding for STAT5A and
STAT5B (11, 12). Signal transduction pathways involved
in STAT activation have been studied in great detail, but
typically involve JAK-mediated phosphorylation of tyro-
sine residues in the SH2 domain of STATs, enabling STAT
dimerization, nuclear translocation, and binding to response
elements in promoters of target genes (11, 12). STAT5 is
activated in response to various hematopoietic cytokines,
including IL-2, IL-3, IL-5, IL-7, GM-CSF, erythropoietin
(EPO), and CSF-1 (13). Activation of STAT5 has been
shown to be required during terminal stages of myeloid dif-
ferentiation (14), eosinophil differentiation of human CB-
derived CD34
 
  
 
cells (15), as well as in early B cells where it
up-regulates PAX5 expression in response to IL-7 (16). In
particular, STAT5 has been implicated in erythropoiesis in
response to EPO and early erythroblast survival by up-reg-
ulating BCL-X
 
L 
 
(17, 18). 
 
Stat5a
 
 
 
/
 
  
 
5b
 
 
 
/
 
  
 
knockout mice
are characterized by fetal anemia and increased apoptosis of
fetal liver erythroid progenitors, although adult steady-state
hematopoiesis was reported to be normal (17, 18). Consis-
tent with these observations, STAT5 has an antiapoptotic
effect in erythroid cell lines and overexpression of domi-
nant negative STAT5 results in increased apoptosis and
growth inhibition of cultured fetal liver erythroid progeni-
tors (17, 19).
Besides the various functions that STAT5 fulfills in nor-
mal hematopoiesis, a constitutive activation of STAT5 has
been observed in a variety of hematological and nonhema-
tological malignancies (20). STAT5 is constitutively acti-
vated in the majority of acute myeloid leukemias (21–24)
and chronic myeloid leukemia (CML; references 25 and
26). A number of chromosomal aberrations, including Flt-
3-ITDs (21), Bcr/Abl (25, 26), and Tel/Jak2 (27) induce
constitutive activation of STAT5, and particularly in the
case of Tel/Jak2, it has been demonstrated that STAT5 is
necessary for Tel/Jak2-induced myeloproliferative disease (27).
Furthermore, the constitutively active mutant STAT5(1
 
*
 
6)
is capable of transforming hematopoietic cell lines to growth
factor independence in vitro (28, 29). These data suggest
that constitutive activation of STAT5 can play a causal role
in leukemic transformation (30).
Because no data were available on the effects of a persistent
activation of STAT5 in human HSCs, we introduced the
STAT5A(1
 
*
 
6) mutant into human stem and progenitor cells
derived from umbilical CB. Here we report that a persistent
activation of STAT5A in human CD34
 
  
 
cells results in en-
hanced self-renewal. STAT5A drives the expression of a
number of proto-oncogenes and cytokines in human CD34
 
 
 
cells, as well as a number of erythroid-specific genes, favoring
erythroid over myeloid differentiation and providing a long-
term proliferative advantage for erythroid progenitors.
 
Materials and Methods
 
Cell Culture and Cell Lines.
 
Neonatal CB was obtained from
healthy full-term pregnancies from the Cord Blood Bank of the
New York Blood Center. CD34
 
  
 
cells (
 
 
 
95% pure) were de-
rived from CB using MiniMACS (Miltenyi Biotec) as described
previously (31). Vesicular stomatitis virus–pseudotyped H29 cells
were cultured in DME (GIBCO BRL) supplemented with 10%
FBS (HyClone Laboratories), penicillin and streptomycin, 200
mM glutamine, 2 
 
 
 
g/ml tetracyclin, 300 
 
 
 
g/ml geneticin, and 2
 
 
 
g/ml puromycin (all obtained from GIBCO BRL). Gibbon ape
leukemia virus–pseudotyped PG13 fibroblasts were grown in
DME supplemented with 10% FBS, penicillin and streptomycin,
and 200 mM glutamine. MS5, OP9, and aorta-gonad-meso-
nephros-S2 (AGM-S2) murine stromal cells were propagated in
 
 
 
MEM (GIBCO BRL) supplemented with 10% FBS, penicillin
and streptomycin, and 200 mM glutamine. For MS5 coculture
experiments and long-term culture–initiating cell (LTC-IC) as-
says, cells were grown in 
 
 
 
MEM supplemented with heat-inacti-
vated 12.5% FBS, heat-inactivated 12.5% horse serum (HyClone
Laboratories), penicillin and streptomycin, 200 mM glutamine,
57.2 
 
 
 
M 
 
 
 
-mercaptoethanol, and 1 
 
 
 
M hydrocortisone (LTC
medium). For OP9 coculture experiments, cells were grown in
 
 
 
MEM supplemented with 12.5% FBS, 12.5% horse serum, pen-
icillin and streptomycin, 200 mM glutamine, 57.2 
 
 
 
M 
 
 
 
-mer-
captoethanol, and 50 
 
 
 
g/ml vitamin C. For AGM-S2 coculture
experiments, cells were grown in 
 
 
 
MEM supplemented with
12.5% FBS, 12.5% horse serum, penicillin and streptomycin, 200
mM glutamine, and 57.2 
 
 
 
M 
 
 
 
-mercaptoethanol. Liquid culture
experiments were performed in IMDM (GIBCO BRL) in the
presence of 10% FBS, 20 ng/ml IL-3, 20 ng/ml IL-6, and c-Kit
ligand (KL), Flt-3 ligand (FL), and thrombopoietin (TPO; 100
ng/ml each; provided by Kirin Brewery Co., Ltd.).
 
Retroviral Vectors, Production, and Transduction.
 
For all retrovi-
ral transduction experiments, the murine stem cell virus retroviral
expression vector was used, which contained an encephalomye-
locarditis virus–derived internal ribosomal entry site (IRES)2 in
front of the enhanced GFP (EGFP; provided by W. Pear, Uni-
versity of Pennsylvania, Philadelphia, PA). The constitutively
active mutant murine STAT5A(1
 
*
 
6) was subcloned from pMX-
puro-STAT5(1
 
*
 
6) into the EcoRI–SalI sites of the pIRES2-
EGFP vector (CLONTECH Laboratories, Inc.). Subsequently,
the BglII–SalI fragment from pSTAT5A(1
 
*
 
6)-IRES2-EGFP was
subcloned into the BglII–XhoI sites from the murine stem cell
virus vector. All constructs were verified by sequencing. Stable
high titer retroviral producer cell lines were generated by tran-
siently transfecting H29 cells using 10 
 
 
 
g DNA and the calcium-
phosphate precipitation method as described previously (32). Af- 
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ter 4 d, supernatants from H29 cultures were used to cross-trans-
duce PG13 cells in the presence of 8 
 
 
 
g/ml polybrene (Sigma-
Aldrich). High titer retroviral producer PG13 cell lines were se-
lected by stringent GFP
 
  
 
cell sorting and/or single cell cloning.
CD34
 
  
 
cells were prestimulated for 48 h in QBSF-60 serum-free
medium (Quality Biological, Inc.) supplemented with 100 ng/ml
TPO, 100 FL, and 100 KL. Retroviral supernatants were har-
vested from stable PG13 producers in QBSF for 8–12 h. Before
the first transduction round, supernatants were collected, 100 ng/
ml TPO, 100 ng/ml FL, 100 ng/ml KL, and 4 
 
 
 
g/ml polybrene
were added, and supernatants were filtered through 0.45-
 
 
 
m fil-
ters (Corning) and used immediately for transduction of CB
CD34
 
  
 
cells on RetroNectin-coated (Takara) six-well plates.
Three consecutive transduction rounds of 8–12 h were per-
formed before starting various assays.
 
Colony-forming Cell (CFC), LTC-IC, and Secondary Cobblestone
Area–forming cell (CAFC) Assays.
 
CFC assays and LTC-IC as-
says on MS5 stromal cells were performed as described previously
(31). In brief, CFC assays were performed in 1.2% methylcellu-
lose containing 30% FBS, 57.2 
 
 
 
M 
 
 
 
-mercaptoethanol, 2 mM
glutamine, 0.5 mM hemin (Sigma-Aldrich), 20 ng/ml IL-3, 20
ng/ml IL-6, 20 ng/ml G-CSF, 20 ng/ml KL, and 6 U/ml EPO.
Week 0 data represent CFCs per 1,000 plated cells, and week 1
and 2 data represent data per 10,000 plated cells. CFU-E assays
were performed as CFC assays in the presence or absence of
EPO, only using 10,000 cells per plate. LTC-IC assays were per-
formed by plating transduced CB CD34
 
  
 
cells in limiting dilu-
tions in the range of 5–100 cells per well on MS5 stromal cells in
48-well plates in LTC medium. For secondary CAFC assays, day
10 CAFCs were harvested by trypsinization of adherent cell pop-
ulations and replated on fresh MS5 stroma or used for analysis or
GFP
 
  
 
sorting.
 
Immunoblotting, Histochemistry, and Cytospins.
 
5 
 
  
 
10
 
5 
 
cells
were lysed on ice in lysis buffer as described previously (32).
Whole cell extracts were boiled for 5 min in Laemmli sample
buffer before separation on 12% SDS-acrylamide gels. Proteins
were transferred to nitrocellulose filters (Millipore) in Tris-glycine
buffer at 9 V for 1.5 h using a semidry electroblotter from Bio-
Rad Laboratories. Membranes were blocked in PBS containing
5% nonfat milk before incubation with antibodies. Binding of an-
tibodies was detected by ECL according to the manufacturer’s in-
structions (Roche Diagnostics). Antibodies against STAT5 (C20)
and GFP (B2) were obtained from Santa Cruz Biotechnology,
Inc. and were used in dilutions of 1:2,000. For histochemistry,
cytospins were fixed in 4% paraformaldehyde, permeabilized in
PBS containing 0.1% Tween-20, and stained with antibodies in
dilutions of 1:100. Secondary Cy2-conjugated antibodies were
obtained from Jackson ImmunoResearch Laboratories and were
used in 1:200 dilutions. Cells were visualized using an inverted
fluorescence microscope (Carl Zeiss MicroImaging, Inc.). May-
Grünwald-Giemsa staining was used to analyze cytospins.
 
PCR and Gene Array Analysis.
 
For RT-PCR, total RNA
was isolated from 10
 
6 
 
cells using the RNeasy kit from QIAGEN
according to the manufacturer’s recommendations. 2 
 
 
 
g RNA
was reverse transcribed with M-MuLV reverse transcriptase
(Roche Diagnostics). For PCR, 2 
 
 
 
l cDNA was amplified using
primers as indicated in the text (sequences and conditions are
available on request) in a total volume of 50 
 
 
 
l using 2 U Taq
polymerase (Roche Diagnostics). As a negative control, RNA
minus reverse transcriptase (
 
 
 
RT)–prepared cDNA was used in
PCR reactions. 10-
 
 
 
l aliquots were run on 1.5% agarose gels.
For microarray analyses, total RNA was isolated from transduced
GFP
 
 
 
-sorted cells using the RNeasy kit from QIAGEN, and 4
 
 
 
g RNA was used for labeling reactions according to the manu-
facturer’s instructions and was hybridized to Affymetrix Human
Genome U133A. MiGR1 and STAT5A(1
 
*
 
6) transcripts were
hybridized independently and gene expression profiles were com-
pared. Differences in gene expression were considered significant
when the fold change was 
 
 
 
1.87 with a detection p-value 
 
 
 
0.05
and a signal value 
 
 
 
200.
Figure 1. Retroviral introduction of
STAT5A(1*6) into human CB CD34 
cells. (A) Schematic representation of the
MiGR1 and STAT5A(1*6) retroviruses
used in this study. (B) CB CD34  cells
were prestimulated for 48 h in QBSF
supplemented with KL, FL, and TPO
(100 ng/ml) followed by three transduc-
tion rounds in the next 48 h with
STAT5A(1*6) or MiGR1 retroviruses,
after which transduction efficiencies
were determined on the basis of GFP
expression using FACS. (C) Western
blot of total extracts from PG13 retroviral
producer cell lines and transduced CB
CD34  cells as described above. Mem-
branes were probed with  -STAT5 and
 -GFP antibodies. (D) Cytospins of
transduced CB CD34  cells. Cytospins
were fixed and permeabilized as de-
scribed in Materials and Methods and
stained with  -STAT5 antibodies.
Transduced cells (T) appear as bright
green with a predominantly nuclear local-
ization of STAT5, whereas the untrans-
duced cells (U) appear as dim. 
STAT5A(1
 
*
 
6) Induces Human HSC Self-Renewal
 
626
 
Mice.
 
Nonobese diabetic (NOD)-SCID mice (also referred
to as NOD/LtSz-SCID) were obtained from The Jackson Labo-
ratory and were maintained in germ-free conditions. Mice were
matched for age (8–10 wk), weight (
 
 
 
20 g), and sex, received a
sublethal dose of 300 cGy total body irradiation, and were in-
jected with 2 
 
  
 
10
 
5 
 
cells via tail vein injection.
 
Flow Cytometry Analysis.
 
All antibodies were obtained from
BD Biosciences. Cells were incubated with antibodies at 4
 
 
 
C for
45 min. For blocking nonspecific binding to Fc
 
  
 
receptors, cells
were blocked with anti-Fc
 
  
 
antibodies for 15 min at 4
 
 
 
C. All
FACS analyses were performed on a FACSCalibur (Becton
Dickinson) and data was analyzed using FlowJo (Tree Star, Inc.).
Cells were sorted on a MoFlo (DakoCytomation).
 
Results
 
Retroviral Introduction of STAT5A(1
 
*
 
6) into Human CB
CD34
 
  
 
Cells.
 
Human umbilical CB–derived CD34
 
  
 
cells
were transduced with either the control bicistronic MiGR1
retroviral vector or the STAT5A(1
 
*
 
6) vector, allowing ex-
pression of a constitutively active mutant of STAT5A (28) as
well as EGFP (Fig. 1 A). Transduction efficiencies were de-
termined by flow cytometric detection of GFP, and MiGR1
transduction efficiencies ranged from 35–60%, whereas the
efficiencies for STAT5A(1
 
*
 
6) ranged from 20–35% (Fig. 1
B). STAT5A(1
 
*
 
6) was strongly overexpressed in both the
PG13 retroviral producer cell line as well as in transduced CB
CD34
 
  
 
cells, as determined by Western blotting (Fig. 1 C).
Constitutive activation of STAT5A(1
 
*
 
6) was demonstrated
by a constitutive nuclear localization of STAT5A(1
 
*
 
6) in
transduced cells using immunofluorescence microscopy (Fig.
1 D). Nontransduced CB CD34
 
  
 
cells expressed low levels of
endogenous STAT5A (Fig. 1 C), which was localized
throughout the cytoplasm and nucleoplasm (Fig. 1 D).
 
STAT5A(1
 
*
 
6) Provides a Proliferative Advantage for CB
CD34
 
  
 
Cells on MS5 Stromal Cells and Induces Erythroid Dif-
ferentiation.
 
To assess the effects of constitutive activation
of STAT5A on the self-renewal and differentiation poten-
tial of HSCs, transduced CB CD34
 
  
 
cells were cultured on
the MS5 murine stromal cell line, and cocultures were
demidepopulated weekly for analysis. Plating of GFP
 
 
 
-
sorted cells on MS5 resulted in a strong expansion of
 
 
 
500-fold of the STAT5A(1
 
*
 
6)-expressing cells, whereas
the MiGR1 control cells expanded only 
 
 
 
50-fold in a
5-wk time period (Fig. 2 A). Plating of nonsorted cells on
MS5 allowed analysis of the relative proliferation of GFP 
and GFP  populations. As depicted in Fig. 2 B, expression
of constitutively active STAT5A(1*6) provided a prolifera-
tive advantage, as the GFP  population of the nonadherent
cells increased from 21 to  80% within 3 wk, whereas the
GFP  MiGR1 population remained constant between 50
and 55%. Similar results were obtained in cocultures with
other stromal cell lines, including OP9 and AGM-S2 (Fig.
2, C and D), and AFT-024 (not depicted). The prolifera-
tive advantage provided by STAT5A(1*6) required the co-
culture on stroma, as this phenotype was not observed in
liquid culture assays in the presence of the cytokines IL-3,
IL-6, KL, FL, and TPO (Fig. 2, E and F).
Morphological and phenotypic analyses revealed that the
STAT5A(1*6)-expanded cells on MS5 were predominantly
committed to the erythroid lineage. Cytospins of week 1
and 2 nonadherent cells showed proerythroblasts, baso-
philic erythroblast, polychromatic and orthochromatic eryth-
roblasts, as well as terminally differentiated erythrocytes
(Fig. 3 A). Flow cytometric analyses revealed elevated
levels of CD36, CD71bright, and glycophorin A (GPA) as
compared with controls, whereas CD45 expression was
strongly reduced (Table I). The myeloid markers CD14
and CD15 were not expressed on STAT5A(1*6) cells,
whereas CD11b expression was reduced, in agreement
with the cytospins in which very few monocytes or macro-
phages and occasional granulocytes could be detected.
These results were further underscored by data obtained
from gene array analyses of transduced GFP -sorted CB
CD34  cells, in which expression of STAT5A(1*6) strongly
Figure 2. CB CD34  cells transduced
with STAT5A(1*6) have a proliferative
advantage in stroma coculture. CB
CD34   cells were transduced with
MiGR1 or STAT5A(1*6) as described
in Fig. 1 and grown in cocultures on
MS5 (A and B), OP9 (C), AGM-S2
(D), or in liquid culture (E and F) in
IMDM in the presence of 10% FCS, 20
ng/ml IL-3, 20 ng/ml IL-6, KL, FL,
and TPO (100 ng/ml each). Cultures
were weekly demidepopulated and cells
were counted and analyzed for GFP ex-
pression by FACS. Data are of a repre-
sentative experiment in triplicate out of
at least three independent experiments.
A and E represent the expansion in ab-
solute cell counts of GFP -sorted cells.
B–D and F represent experiments started
with unsorted cells and indicate the per-
centage of GFP  cells. Week 0 repre-
sents transduced cells before plating on
stroma or liquid cultures.Schuringa et al. 627
induced the expression of the erythroid markers CD36,
glycophorin A and B, and hemoglobins  ,  ,  , and  ,
whereas genes associated with myeloid differentiation were
down-regulated (see below).
The amount of progenitors in the MS5 cocultures was
enumerated in colony assays in methylcellulose. Trans-
duced CB CD34  cells were either plated directly for CFC
assays (week 0) or on MS5 for expansion and weekly
demidepopulation (weeks 1 and 2). As depicted in Fig. 3 B,
overexpression of STAT5A(1*6) resulted in a shift to
mostly erythroid burst-forming units (BFU-E) and some
mixed and CFU-GM progenitors within 48 h after the start
of the transduction (week 0), whereas the MiGR1 cells
contained mostly CFU-GM colonies and some mixed
and BFU-E colonies. These differences were further pro-
nounced in MS5 cocultures in which the nonadherent cells
of the STAT5A(1*6) coculture contained mostly BFU-E
and some mixed colonies at weeks 1 and 2, whereas few
CFU-GM progenitors were present (Fig. 3 B). In contrast,
MiGR1 cells gave rise to mostly CFU-GMs at weeks 1 and
2 (Fig. 3 B). Furthermore, week 2 nonadherent cells from
the MS5 coculture were plated in CFU-E assays in methyl-
cellulose in the absence or presence of EPO. As indicated
in Fig. 3 C, STAT5A(1*6) cells generated a significant
number of erythroid colonies (CFU-E) in the absence of
EPO, which was further enhanced by the addition of EPO.
In contrast, control MiGR1 cells did not give rise to CFU-E
on MS5 (Fig. 3 C). Morphological analyses demonstrated
that most of the colonies consisted of terminally differenti-
ated enucleated erythrocytes (Fig. 3 C, inset).
Taken together, these data indicate that STAT5A(1*6) pro-
vides a proliferative advantage for CB CD34  cells on stroma
and drives erythroid, but blocks myeloid, differentiation.
STAT5A(1*6) Induces Early Cobblestone Areas on Stroma
with Self-Renewing Potential. In coculture studies on vari-
ous stromal cell lines, we noted the appearance of very
early CAFCs with STAT5A(1*6)-transduced CB CD34 
cells within 10 d after plating (Fig. 4 A). These early
CAFCs were not observed with MiGR1-transduced cells,
which did develop the classical week 5 CAFCs on MS5
stroma. To enumerate the CAFC frequencies, LTC-IC as-
says were performed under limiting dilution conditions us-
ing GFP -sorted CB CD34  cells transduced with MiGR1
or STAT5A(1*6). As indicated in Fig. 4 B, the expression
of constitutively active STAT5A(1*6) resulted in a CAFC
frequency of 12–13% at day 10, and most of these early
CAFCs continued to grow until week 5. In contrast, CB
CD34  cells transduced with MiGR1 generated CAFCs on
MS5 with a frequency of 0.5–1% at week 5 (Fig. 4 B).
These data indicate that besides the shift from week 5
to day 10 cobblestones, the frequency is strongly enhanced
in cells that express STAT5A(1*6). Phenotypical analysis
of the day 10 CAFCs generated by overexpression of
STAT5A(1*6) revealed that  5% of the cells expressed
CD34, 65% were CD71bright, and 25% expressed GPA. The
myeloid markers CD14, CD15, and CD19 were not ex-
pressed and only  12% expressed CD45 (Fig. 4 C). As a
control, day 10 adherent GFP  MiGR1-transduced cells
were analyzed, which at this time had not developed into
CAFCs. These cells expressed CD14 and CD45, whereas
 1% expressed CD34 and no GPA expression could be
detected. These data indicate that the early CAFCs induced
by STAT5A(1*6) contain erythroid progenitors, more
committed erythroid cells, and some CD34  cells, but few
myeloid cells. This was further underscored by morpholog-
ical analysis of GFP -sorted adherent cells from cocultures
Figure 3. Overexpression of STAT5A(1*6) in CB CD34  cells induces
erythroid differentiation. CB CD34  cells were transduced with MiGR1
or STAT5A(1*6) as described in Fig. 1 and grown in cocultures on MS5.
Cultures were weekly demidepopulated, nonadherent cells were counted
and used for cytospins (A), CFC assays (B), or CFU-E assays (C), as described
in Materials and Methods. Week 0 represents transduced cells before plating
on MS5 stroma. The arrows in A indicate the following: 1, proerythro-
blasts; 2, basophilic erythroblasts; 3, polychromatic and orthochromatic
erythroblasts; and 4, erythrocytes.STAT5A(1*6) Induces Human HSC Self-Renewal 628
on MS5 at day 10. Although the adherent population in
the MiGR1 cells contained mostly myeloid cells, the
STAT5A(1*6) cells contained erythroid progenitors, more
committed erythroid cells, and some cells with a blast-like
morphology, but few myeloid cells (Fig. 4 D).
To determine whether the early CAFCs induced by
STAT5A(1*6) represent true HSCs, a variety of assays were
undertaken. First, transduced CB CD34   cells were
sorted  into GFP /CD38low and GFP /CD38high popula-
tions, which were analyzed for CAFC activity on MS5 un-
der limiting dilution conditions. As indicated in Fig. 4 E,
most of the CAFCs at day 10 arose from the CD38low pop-
ulation with a frequency of 13.8%, whereas the CD38high
population contained some CAFCs at a frequency of 4.5%.
Importantly, only the CAFCs generated by the GFP /
CD38low population gave rise to secondary CAFCs when
plated onto fresh MS5 stroma, whereas the CAFCs gener-
ated from the GFP /CD38high population did not (Fig. 4
E). Differentiated progeny from secondary CAFCs from
the GFP /CD38low population was monitored by flow cy-
tometry and cytospins. Secondary CAFCs predominantly
gave rise to erythroid cells and some myeloid cells (not de-
picted; see also Fig. 5). Furthermore, day 10 CAFCs were
plated in methylcellulose to determine the presence of he-
matopoietic progenitors. Most of the progenitors were
found to be in the CAFCs generated by the GFP /
CD38low population and contained mostly BFU-E, some
CFU-GM, and mixed colonies (Fig. 4 F). To establish the
effect of STAT5A(1*6) expression on the self-renewal of
immature progenitors, we also performed secondary CFC
assays with transduced CD34  cells in which primary colo-
nies from CFC assays in methylcellulose were harvested
and plated for secondary CFCs. As illustrated in Fig. 4 G,
expression of STAT5A(1*6) resulted in the appearance of
significant numbers of secondary CFCs, most of which
were myeloid. In contrast, MiGR1 CFCs did not generate
secondary CFCs (Fig. 4 G). Finally, sublethally irradiated
NOD-SCID recipients were injected with 2   105 GFP 
day 10 STAT5A(1*6) CAFCs. Mice were killed at week 6
and the bone marrow was analyzed for GFP  and CD45 
populations. A typical analysis is shown in Fig. 4 G, and
graft efficiencies were in the range of 0.1–1% (n   4), indi-
cating that the early CAFCs generated by overexpression of
STAT5A(1*6) contain cells that are able to engraft in a sub-
lethally irradiated host in vivo. Further analysis indicated
that the donor-derived STAT5A(1*6) GFP  cells were pre-
dominantly CD36  and CD45 , whereas few CD11b  do-
nor-derived cells were detected in NOD-SCID mice
injected with STAT5A(1*6) CAFCs. Interestingly, a signif-
icant number of cells positive for human GPA were GFP .
Possibly some of the GPA  cells are negative for GFP due
to quenching by the heme group found within red cells.
These data suggest that the STAT5A(1*6) CAFCs contain
HSCs or early progenitors that engraft NOD-SCID mice
and differentiate toward the erythroid lineage in vivo. In
NOD-SCID engraftment studies in which MiGR1 and
STAT5A(1*6) CD34  cells were injected directly after
transduction (n   8 for MiGR1 and STAT5A(1*6)), we
observed comparable engraftment levels of 0.5–1.5% for
both MiGR1 and STAT5A(1*6). FACS analysis of the pe-
ripheral blood cells with CD11b, CD15, CD36, and CD19
showed donor-derived cells in erythroid, myeloid, and
lymphoid lineages (not depicted).
Activation of STAT5A Allows Long-Term Cultures of CAFCs
on MS5 for up to 18 wk. We wished to determine for
how long early CAFCs generated by overexpression of
STAT5A(1*6) could be serially passaged onto new MS5
stroma. Day 10 CAFCs were harvested and plated on fresh
MS5 stroma to allow generation of secondary CAFCs. Sec-
ondary CAFCs were formed readily within 10–20 d with
Table I. Phenotype of Nonadherent Cells from Cocultures of Transduced CB CD34  Cells on MS5 Stroma (in Percent)
Week 0a Week 1 Week 2
MiGR1 STAT5A(1*6) MiGR1 STAT5A(1*6) MiGR1 STAT5A(1*6)
CD34 92 93 10 11 1–4 1–4
CD38 64 35 59  18 41 8
CD33 99 99 84 8 78 17
CD36 34 65 31 57 24 47
CD71bright 29 35 15 65 13 26
CD45 99 99 88 14 95 7
GPA  1 7.5 10 64 5 41
CD11b 11 6 53 3 68 14
CD14  1  1 45 4 27 2
CD15  1  1 12 0 23 3
aWeek 0 represents analysis after 48 h of prestimulation followed by 48 h of transduction of CB CD34 
 cells in QBSF with KL, FL, and TPO (100
ng/ml of each) before plating cells on MS5 stroma. Data represent the average percentages of two to five independent experiments.Schuringa et al. 629
the STAT5A(1*6) cells, generating approximately four to
five secondary CAFCs per initial CAFC. Moreover,
STAT5A(1*6) CAFCs could be serially passaged for up to
18 wk. A typical experiment out of two independent exper-
iments is shown in Fig. 5, in which CAFCs were plated
onto new MS5 at day 10, weeks 3, 5, and 7 (not depicted),
and weeks 10, 13, and 15, continuously generating new
CAFCs and nonadherent cells for up to 18 wk (Fig. 5 A).
Cocultures were weekly demidepopulated and analysis of
nonadherent cells at week 14 revealed that STAT5A(1*6)
RNA was still being expressed (Fig. 5 B) and that cells were
mostly erythroid, somewhat resembling an erythroleukemia
(Fig. 5 C). These cells still generated significant numbers of
progenitors as determined by CFC assays, all of which were
BFU-E (Fig. 5 D). These results were further underscored
by FACS analysis of nonadherent cells at week 14: 1.5% ex-
pressed CD34, 30% expressed CD36, 55% were CD71bright,
and 4.5% were GPA , whereas no CD14  and CD15 
cells, and few CD45  (11%) and CD11b  (10%) cells, were
detected (not depicted). Taken together, these data indicate
that overexpression of constitutively active STAT5A(1*6)
allows the generation of early CAFCs with long-term self-
renewal capacity on MS5 ex vivo.
Molecular Analysis of Overexpression of Constitutively Active
STAT5A(1*6) in CB CD34  Cells. To obtain more in-
sight in the underlying mechanisms involved in the pheno-
types we observed by overexpression of STAT5A(1*6) in
CB CD34  cells, microarray analysis was performed using
the Affymetrix Human Genome U133A gene arrays that
contain  21,000 probe sets. CB CD34  cells were trans-
duced with MiGR1 or STAT5A(1*6), total RNA was iso-
lated from GFP -sorted cells, and labeled cDNA was pre-
pared for hybridization with the gene arrays. MiGR1 and
STAT5A(1*6) transcripts were hybridized independently,
Figure 4. STAT5A(1*6) induces early CAFCs in CB CD34 
cells. CB CD34   cells were transduced with MiGR1 or
STAT5A(1*6) as described in Fig. 1 and grown in cocultures on
stromal cell lines as indicated. (A) Representative examples of
CAFCs at day 10 observed in coculture studies with CB CD34 
cells transduced with STAT5A(1*6). (B) CAFC frequencies were
determined on MS5 in limiting dilution conditions as described in
Materials and Methods. (C) GFP  cells were sorted from the ad-
herent population on MS5 at day 10 and used for FACS analysis
and cytospins (D). (E) CB CD34  cells were transduced with
MiGR1 or STAT5A(1*6), after which the CD38high and CD38low populations were sorted and used to determine the CAFC frequencies on MS5 under
limiting dilution conditions. First CAFC frequencies were determined at day 10, and cultures were either harvested and plated on new MS5 stroma to determine
secondary CAFC frequencies (indicated in black as number of secondary CAFCs/number of primary CAFCs), or plated in methylcellulose to determine
the number of CFCs/10 CAFCs (F). (G) CB CD34  cells were transduced with MiGR1 or STAT5A(1*6) as described in Fig. 1 and plated for CFC assays
in triplicate. After 2 wk, the colonies were scored and cells from each plate were plated for secondary CFCs. (H) Sublethally irradiated NOD-SCID recipients
were injected with 2   105 GFP  day 10 STAT5A(1*6) CAFCs. Mice were killed at week 6 and the bone marrow was analyzed as indicated.STAT5A(1*6) Induces Human HSC Self-Renewal 630
Table II. Differential Gene Expression in CB CD34  Cells Expressing STAT5A(1*6)
Gene Unigene accession Gene symbol Fold changea
hemoglobin,   Hs.272003 HBZ 42.22
glycophorin A (includes MN blood group) Hs.108694 GYPA 12.13
FBJ murine osteosarcoma viral oncogene homologue B Hs.75678 FOSB 11.31
aquaporin 3 Hs.234642 AQP3 4.92
leukemia inhibitory factor (cholinergic differentiation factor) Hs.2250 LIF 4.92
hemoglobin,  2 Hs.347939 HBA2 3.73
hemoglobin,  1 Hs.272572 HBA1 3.73
glycophorin B (includes Ss blood group) Hs.343871 GYPB 3.73
monoamine oxidase A Hs.183109 MAOA 3.25
pim-1 oncogene Hs.81170 PIM1 3.25
ankyrin 1, erythrocytic Hs.183805 ANK1 3.25
TNF receptor–associated factor 4 Hs.8375 TRAF4 3.25
cytokine-inducible SH2-containing protein Hs.8257 CISH 3.03
hemoglobin,  A Hs.266959 HBG1 3.03
hemoglobin, ε1 Hs.117848 HBE1 2.83
leptin receptor Hs.226627 LEPR 2.64
Rhesus blood group–associated glycoprotein Hs.169536 RHAG 2.64
ankyrin 1, erythrocytic Hs.183805 ANK1 2.46
ras-related C3 botulinum toxin substrate 3 (rho family, Rac3) Hs.45002 RAC3 2.46
Kell blood group precursor (McLeod phenotype) Hs.78919 XK 2.46
CD36 antigen (collagen type I receptor) Hs.75613 CD36 2.30
PDGFA-associated protein 1 Hs.278426 PDAP1 2.14
son of sevenless homologue 1 (Drosophila) Hs.326392 SOS1 1.87
vascular endothelial growth factor Hs.73793 VEGF 1.87
FOS-like antigen 2 Hs.301612 FOSL2  1.87
absent in melanoma 1 Hs.161002 AIM1  1.87
T cell receptor   locus Hs.303157 TRB  1.87
CD44 antigen (homing function) Hs.169610 CD44  1.87
RAB27A, member RAS oncogene family Hs.50477 RAB27A  1.87
platelet/endothelial cell adhesion molecule (CD31 antigen) Hs.78146 PECAM1  1.87
TYRO protein tyrosine kinase binding protein Hs.9963 TYROBP  1.87
myeloperoxidase Hs.1817 MPO  1.87
v-myc myelocytomatosis viral-related oncogene (avian) Hs.25960 MYCN  2.00
cathepsin G Hs.100764 CTSG  2.00
elastase 2, neutrophil Hs.99863 ELA2  2.00
CCAAT/enhancer binding protein (C/EBP),   Hs.76722 CEBPD  2.00
immunoglobulin heavy constant   Hs.153261 IGHM  2.14
caspase 1, apoptosis-related cysteine protease  Hs.2490 CASP1  2.14
CD48 antigen (B cell membrane protein) Hs.901 CD48  2.46
chemokine (C-X-C motif), receptor 4 (fusin) Hs.89414 CXCR4  2.64
B cell CLL/lymphoma 6 (zinc finger protein 51) Hs.155024 BCL6  2.64
CCAAT/enhancer binding protein (C/EBP),   Hs.76171 CEBPA  3.25
aCB CD34  cells were prestimulated for 48 h in QBSF with KL, FL, and TPO (100 ng/ml of each) followed by three transduction rounds in the
next 48 h. GFP  cells were sorted and total RNA was isolated and used to hybridize gene arrays. Data shown is the comparison of GFP 
STAT5A(1*6) versus GFP  MiGR1 cells. A change in gene expression was only considered significant when the fold change was  1.87 with a sta-
tistical p-value of  0.05 and a signal value of  200.Schuringa et al. 631
and gene expression profiles were compared. The most im-
portant results are shown in Table II. Changes of expression
patterns of genes that were possibly related to our observed
phenotypes were further confirmed by RT-PCRs in two
independent preparations of total RNA from GFP -sorted
CB CD34  cells (Fig. 6 A). 137 genes were differentially ex-
pressed in CB CD34  cells transduced with STAT5A(1*6)
versus MiGR1, 84 genes were up-regulated, and 53 genes
were down-regulated. 25 of the 137 genes encoded for hy-
pothetical proteins or expressed sequence tags.
The genes that were up-regulated by STAT5A(1*6) in-
cluded many that are associated with erythroid differentia-
tion, such as the hemoglobins  ,  1,  2,  A, and  1, and
the glycophorins A and B. Also, an up-regulation was
found of ankyrin 1, rhesus blood group–associated glyco-
protein, Kell blood group precursor, and CD36. GATA1
was expressed in CB CD34  cells, but was not significantly
up-regulated by STAT5A(1*6). In contrast, some of the
genes that have been associated with myeloid differentia-
tion were down-regulated, including cathepsin G, CD31,
elastase 2, C/EBP , C/EBP , and CD44 and CD48. These
data reflect the observations from coculture studies of trans-
duced CB CD34  cells on MS5 stroma in which we ob-
served a strong erythroid differentiation, whereas myeloid
differentiation was blocked. Other genes of interest include
the proto-oncogenes FOS-B and PIM1, which both have
been associated with enhanced cell proliferation and sur-
vival. Caspase 1 was down-regulated, whereas LIF and
VEGF were up-regulated.
Interestingly, no effects were found on known STAT5A
target genes related to cell cycle progression and antiapop-
tosis, such as CyclinD1, BCL2, and BCL-XL within 48 h of
expression in CB CD34  cells (Fig. 6 A and microarray
data). However, RT-PCR analysis of nonadherent cells
from week 2 MS5 cocultures revealed that both BCL2 and
BCL-XL  were up-regulated as compared with control
MiGR1 cells, suggesting that STAT5A(1*6) protects cells
from apoptosis in our coculture studies by up-regulating
these proteins.
Discussion
A variety of hematopoietic growth factors and cytokines
have been shown to induce phosphorylation of STAT5, al-
though functional data on the effects of STAT5A activation in
human hematopoietic cells is still limited. Here, we show that
a persistent activation of STAT5A in CB CD34  cells results
in enhanced human HSC self-renewal and erythropoiesis.
One critical component in the phenotypes observed
by overexpression of the constitutively active mutant
STAT5A(1*6) in CB CD34  cells is the interaction of HSCs
with the surrounding stroma. Within a few days after plat-
ing, CB CD34  cells transduced with STAT5A(1*6) form
CAFCs on various stromal cell lines, including MS5, and
these CAFCs can be cultured for at least up to 18 wk. Typi-
cally, the production of CAFCs at weeks 5 or 6 in ex vivo
expansion cultures has been shown to be indicative of the
presence and quantity of in vivo long-term repopulating
HSCs, as measured using the quantitative NOD-SCID
transplantation model, whereas CAFCs arising earlier have
been associated with short-term engrafting cells (33–36). In
the case of overexpressed STAT5A(1*6), the CAFCs that
arise within 5–10 d can be grown for at least 18 wk by serial
passage on new stromal cells every 2–3 wk, giving rise to
nonadherent progeny that is mostly erythroid, but also con-
tains a small subset of CD11b  myeloid cells, suggesting that
Figure 5. Long-term cultures of CB
CD34  cells transduced with STAT5A(1*6)
on MS5 stroma. (A) CB CD34  cells were
transduced with STAT5A(1*6) and plated
on MS5 to generate CAFCs, which were
harvested and replated onto new MS5 at
day 10, weeks 3, 5, and 7 (not depicted),
and weeks 10, 13, and 15 (indicated by the
arrows). Cultures were weekly demidepop-
ulated and cell counts of a representative ex-
periment out of two independent experi-
ments are shown. At week 14, nonadherent
cells were used for FACS analysis (see Table
I), RT-PCR analysis (B), in which total
RNA was isolated, and used in RT-PCR
reactions with primers that amplify the
STAT5A(1*6)-IRES2 cassette, cytospins
(C), or CFC assays (D), in which cells were
plated in methylcellulose.STAT5A(1*6) Induces Human HSC Self-Renewal 632
these CAFCs represent self-renewing cells with the capacity
to give rise to predominantly erythroid and, to a lesser ex-
tent, myeloid progeny. Interestingly, in liquid cultures,
STAT5A(1*6)-transduced cells did not have a proliferative
advantage over control MiGR1 cells, as observed in stromal
cocultures. Also, no pronounced erythroid differentiation
was observed in STAT5A(1*6) cells in liquid cultures. These
data indicate that the interaction with stroma is critical for
the self-renewal, proliferative advantage, and erythropoiesis
of STAT5A(1*6)-expressing cells. Perhaps, VEGF or LIF,
which are both up-regulated in CB CD34  cells transduced
with STAT5A(1*6), are critical in ensuring an appropriate
microenvironment for HSC self-renewal in stromal niches, a
possibility that will certainly be a focus of future research.
Indeed, it has been demonstrated that LIF can up-regulate
the production of stem cell expansion–promoting factors in
stromal cells, enabling the maintenance of highly enriched
competitive repopulating stem cells (37–39).
Although in control cells  1 in 100 cells will give rise to
a CAFC at week 5 on MS5, in STAT5A(1*6)-expressing
cells this has increased to  12 in 100 cells within 10 d.
Upon secondary passage, one STAT5A(1*6) CAFC gave
rise to four to five secondary CAFCs. The self-renewing
HSCs reside in the immature CD34 /CD38low population.
In experiments in which GFP /CD34 /CD38low  and
GFP /CD34 /CD38high populations were sorted directly
after transduction and analyzed for CAFC, secondary
CAFC, and CFC/CAFC ratios, we found that the
CD38high fraction contains some CAFCs, but no secondary
CAFCs and few CFCs/CAFC, whereas the majority of
CAFCs, secondary CAFCs, and CFC/CAFC activities was
present in the CD38low population. The CAFCs generated
by this CD34 /CD38low fraction contained mostly BFU-E
progenitors and some CFU-GM and CFU-mix progeni-
tors (Fig. 4 F). The secondary CAFCs generated predomi-
nantly erythroid and some myeloid cells (not depicted). Al-
though it has been described that the CD34 /CD38low
population contains both long-term and short-term repop-
ulating stem cells, our data indicate that a persistent activa-
tion of STAT5A imposes self-renewal characteristics on
this population. Microarray and RT-PCR analyses re-
vealed that STAT5A(1*6) does not enhance the expression
of genes that have previously been associated with HSC
self-renewal, such as HOXB4, NOTCH1, BMI11, or
 -catenin (4–7, 9), although these genes are being ex-
pressed, as determined by our microarray analysis (not de-
picted). The proto-oncogenes FOSB and PIM1 were up-
regulated in CB CD34  cells, and PIM1 has previously
been identified as a STAT5 target gene (40). In particular,
PIM1 has been associated with enhanced cell proliferation,
cytokine independent growth, and cellular transformation
processes (28, 41–43), and it will be of interest to deter-
mine its role in HSC self-renewal.
The early CAFCs can engraft sublethally irradiated
NOD-SCID mice with frequencies of 0.1–1%. As we in-
jected 2   105 GFP  CAFCs into NOD-SCID mice, of
which  5% were CD34 , these engraftment frequencies
are comparable to those that have been reported for fresh
CB (33). It has been suggested that upon plating on stromal
cells, HSCs are initially in a quiescent state and reside in a
nonproliferative niche, comparable to the situation in the
bone marrow under nonmyelosuppressive conditions (44).
Bone marrow ablation induces the release of soluble KL,
enabling bone marrow–repopulating cells to translocate to
a permissive vascular niche, favoring differentiation and re-
constitution of the stem/progenitor cell pool (44). On
stroma, stem cells start to proliferate within 5 wk, giving
rise to CAFCs with in vivo multilineage reconstitution po-
tential. As overexpression of STAT5A(1*6) results in a shift
toward early CAFCs, we hypothesize that these HSCs are
less quiescent, but rather “activated,” resulting in the gen-
eration of CAFCs with long-term self-renewal potential ex
vivo. Recently, Bradley et al. (45) reported that under
Figure 6. RT-PCR analysis of CB CD34   cells transduced with
STAT5A(1*6) versus MiGR1. (A) CB CD34  cells were prestimulated for
48 h in QBSF supplemented with KL, FL, and TPO (100 ng/ml of
each)  followed by three transduction rounds in the next 48 h with
STAT5A(1*6) or MiGR1 retroviruses. Total RNA was isolated and used
in RT-PCR reactions as described in Materials and Methods, and used for
RT-PCR reactions. (B) RT-PCR analysis as in A, but on total RNA iso-
lated from the week 2 nonadherent cells from MS5 cocultures.Schuringa et al. 633
5-FU–induced myelosuppressive conditions, stat5a /  b / 
repopulating stem cells are indeed more quiescent and
much less responsive to early-acting cytokines that may
play a role in repopulation. These observations and our
data suggest that STAT5 fulfills an important function in
the hematopoietic reconstitution and self-renewal proper-
ties of HSCs.
Although expression of STAT5A(1*6) in CB CD34 
cells results in the generation of CAFCs that can be cul-
tured for up to 18 wk, give rise to new CAFCs with ev-
ery passage, and engraft sublethally irradiated NOD-SCID
mice, we cannot rule out the possibility that STAT5A ac-
tivity promotes the expansion and self-renewal of early ery-
throid progenitors with reconstitution potential rather than
true HSC expansion and self-renewal. Clearly, most of our
data, including ex vivo long-term cultures on MS5 and in
vivo hematopoietic reconstitution studies in NOD-SCID
mice, indicate that cells predominantly differentiate along
the erythroid lineage, which would support such a model.
Nevertheless, after 18 wk on MS5, we still find  10%
CD11b  cells. In secondary CFCs assays, we observed that
only STAT5A(1*6) cells give rise to secondary CFCs,
which are mostly CFU-GMs, suggesting that STAT5A(1*6)
promotes self-renewal of an early cell that certainly can
give rise to myeloid progeny. The CAFCs generated by
STAT5A(1*6) still contained significant amounts of CFU-
GM and CFU-mixed progenitors (Fig. 4 F), and upon
long-term culture on MS5, we observed a gradual loss of
myeloid progenitors. Further studies in which STAT5A(1*6)
is expressed in various sorted subsets, including early HSCs
and more differentiated erythroid and myeloid progenitors,
are currently ongoing and will help to clarify some of these
issues.
Our data are in agreement with previously published ob-
servations in mice that have suggested a role for STAT5 in
HSC self-renewal (45–47). In competitive repopulation as-
says, bone marrow and fetal liver cells of stat5a /  b /  mice
displayed a decreased repopulating activity in granulocyte,
macrophage, erythroid, and B lymphocyte populations,
with no detectable engraftment of T lymphocytes (46).
These results indicated that a significant proportion of the
growth factor signals required for multilineage reconstitu-
tion potential of HSCs is dependent on STAT5. In a similar
study, Snow et al. (47) also demonstrated that STAT5-null
HSCs have a profound impairment in repopulating poten-
tial, and they suggested that STAT5 is required to sustain a
robust hematopoietic reserve that contributes to host viabil-
ity through crucial survival effects on early progenitor cells.
These data indicate that although STAT5-deficient mice
are viable and steady-state hematopoiesis is fairly normal,
STAT5A/B is an important positive factor for HSC fitness
and multilineage hematopoiesis. Our data indicate that con-
stitutive activation of STAT5 is in fact sufficient for long-
term human HSC self-renewal. Currently, studies are on-
going to further evaluate the effects of STAT5A(1*6) on
multilineage reconstitution potential of human HSCs in
vivo in NOD-SCID mice, and we have observed similar
phenotypes in murine embryonic stem cell–derived he-
matopoietic cells in which overexpression of STAT5A(1*6)
facilitates hematopoietic differentiation and results in long-
term HSC self-renewal in vitro and in vivo (48).
Although adult mice lacking STAT5A/B have normal
hematocrit and hemoglobin concentrations, stat5a /  b / 
embryos are severely anemic due to massive apoptosis and a
reduced response to EPO (17, 18). These findings and oth-
ers have implicated STAT5 in EPO downstream signaling
and have suggested an antiapoptotic role for STAT5A in
erythroid progenitors by up-regulating genes such as bcl-xL.
Besides effects on antiapoptosis, our studies indicate that a
persistent activation of STAT5A directly drives erythro-
poiesis by up-regulating genes involved in erythroid differ-
entiation. It will be of interest to determine whether the
promoters of the STAT5A(1*6)–up-regulated erythroid
genes contain bona fide STAT5 binding elements or
whether these genes are up-regulated via an indirect mech-
anism. Furthermore, BCL2 and BCL-XL were not up-reg-
ulated by STAT5A(1*6) within 48 h of expression in CB
CD34  cells, as determined by microarray analysis as well as
by RT-PCR, whereas an increase of these transcripts was
observed in week 2 nonadherent cells from MS5 cocul-
tures. These data suggest that initially STAT5A(1*6) drives
erythroid differentiation by the up-regulation of critical er-
ythroid genes (and/or the concomitant down-regulation of
other lineage-specific genes), whereas in later phases during
differentiation STAT5 will also play a role in the survival of
erythroid progenitors by preventing apoptosis.
Finally, our data provide some important insights into the
possible roles that STAT5 proteins might play in the develop-
ment of leukemic malignancies. A constitutive activation of
STAT5 has been observed in acute myeloid leukemia (21–
24), CML (25, 26), and idiopathic myelofibrosis (49), either as
a result of chromosomal translocations such as Bcr/Abl in the
case of CML, or possibly due to a disturbed cytokine produc-
tion by leukemic blasts themselves or the surrounding stroma
(50, 51). Our data indicate that a persistent activation of
STAT5A in HSCs results in enhanced self-renewal, whereas
differentiation along the myeloid lineage toward macrophages
and granulocytes is severely impaired. Evidence is now accu-
mulating that suggests that acute leukemias are clonal disorders
in which blastic cells have stem cell self-renewal characteristics
with a concomitant block in differentiation toward mature
blood cells (52, 53). It is now conceivable that a persistent acti-
vation of STAT5A might play a causal role in the develop-
ment of such disorders in humans and it would therefore be of
great interest to develop therapeutically agents that specifically
inhibit STAT5. Little is known about the activation patterns
of STAT5 in erythroleukemias in humans, but this is certainly
a focus of future research, as our data directly indicate that a
constitutive activation of STAT5 is sufficient to drive erythro-
poiesis at the expense of myeloid differentiation.
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